Table 1

Pharmacokinetic parameters for 125I-OX26 in rats treated with either saline, mIgG2a, or OX26 MAb

ParameterSalinemIgG2aOX26
A 1 (% ID/ml)1.13  ± 0.151.34  ± 0.171.46  ± 0.44
A 2 (% ID/ml)3.05  ± 0.033.79  ± 0.072.92  ± 0.25
K 1 (min−1)0.27  ± 0.070.52  ± 0.270.69  ± 0.42
K 2(min−1)0.0058  ± 0.00030.0063  ± 0.00060.010  ± 0.001
t½,1 (min)2.92  ± 0.612.23  ± 0.971.87  ± 0.72
t½,2 (min)120  ± 6112  ± 1173  ± 8
AUC0–60 (% ID/min/ml)159  ± 3194  ± 9165  ± 13
AUC0–∞ (% ID/min/ml)531  ± 34618  ± 76372  ± 12
V c (ml/kg)1-a 97  ± 481  ± 285  ± 14
V ss (ml/kg)130  ± 2108  ± 2115  ± 15
CL(ml/min/kg)0.76  ± 0.050.68  ± 0.071.10  ± 0.09
MRT (min)171  ± 9160  ± 16104  ± 12
  • The pharmacokinetic parameters were estimated from the plasma profile data in fig. 1. Data are mean ± SE (N = 3 animals in each group).

  • 1-a Vc, central compartment volume;Vss, steady-state volume of distribution;CL, plasma clearance; MRT, mean residence time.